FDA Reviews Feraheme Label Expansion

Share this content:

AMAG Pharmaceuticals announced that the FDA has accepted for review its supplemental New Drug Application (sNDA) to expand the indication for Feraheme (ferumoxytol) injection for IV use to adult patients with iron deficiency anemia (IDA) who have failed or could not take oral iron treatment. Feraheme injection for IV use is currently indicated for the treatment of iron deficiency anemia in adult chronic kidney disease (CKD) patients.

The sNDA submission is based on data from a global Phase 3 program that evaluated the use of ferumoxytol in a broad range of adult IDA patients, all of whom had failed or could not take oral iron treatment. More than 1,400 patients were enrolled in the two Phase 3 clinical trials (IDA-301, a placebo comparator and IDA-302, an active comparator). Both studies achieved their primary efficacy endpoints, with statistically significant improvements in hemoglobin from baseline to the 35-day endpoint of the studies.

For more information call (617) 498-3300 or visit www.amagpharma.com
You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters